Stay updated on Nivolumab + HF10 for Resectable Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.

Latest updates to the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page
- Check6 days agoChange DetectedThe page header/footer was updated to a new site software revision version (v3.5.3 instead of v3.5.2) without any accompanying changes to the study record content.SummaryDifference0.1%

- Check13 days agoChange DetectedRevision updated to v3.5.2. Melanoma and the related topic MedlinePlus Genetics, along with the Revision: v3.5.0 reference, were removed.SummaryDifference0.2%

- Check20 days agoChange DetectedAdded Melanoma as a topic and MedlinePlus Genetics under related topics; no deletions were made.SummaryDifference0.2%

- Check28 days agoChange DetectedThe Melanoma topic and the MedlinePlus Genetics link were removed from the Related Topics section. This reduces quick access to disease context and related educational resources.SummaryDifference0.2%

- Check42 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check56 days agoChange DetectedAdded related topics Melanoma and MedlinePlus Genetics. Updated site revision from v3.4.2 to v3.4.3.SummaryDifference0.2%

Stay in the know with updates to Nivolumab + HF10 for Resectable Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.